A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered HEC96719 Tablets in Adult Patients With Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis
Latest Information Update: 23 Feb 2024
At a glance
- Drugs HEC 96719 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Sunshine Lake Pharma
Most Recent Events
- 20 Feb 2024 Status changed from recruiting to completed.
- 10 Apr 2023 Planned End Date changed from 30 Dec 2022 to 30 Dec 2023.
- 10 Apr 2023 Planned primary completion date changed from 30 Dec 2022 to 30 Dec 2023.